Larvol Veri

BIOMARKER:

MAP2K1 P124S

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

MAP2K1 P124S MAP2K1 P124S	Melanoma Melanoma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
MAP2K1 P124S MAP2K1 P124S	Melanoma Melanoma	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3
MAP2K1 P124S MAP2K1 P124S	Melanoma Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
MAP2K1 P124S MAP2K1 P124S	Melanoma Melanoma	selumetinib Sensitive: C4 – Case Studies selumetinib Sensitive : C4
MAP2K1 P124S MAP2K1 P124S	Melanoma Melanoma	PLX4720 Resistant: D – Preclinical PLX4720 Resistant : D